Ashtanga Vaidyam Ayurvedics

Ashtanga Vaidyam Ayurvedics, also known as K.S. Varier's Ashtanga Ayurvedics Private Limited, was established in 1999 and is headquartered in Trichy, Tamil Nadu, India. The company specializes in the manufacturing of Ayurvedic pharmaceutical formulations, including tablets, capsules, syrups, and injections. As a private limited entity, it is classified under the Corporate Identification Number (CIN) U24233TN1999PTC041899. The authorized capital stands at ₹2.00 crore, with a paid-up capital of ₹1.85 crore. The latest available financial data indicates that the company is active and operational. For more information, the official website is ashtangam.com.

Ashtanga Vaidyam Ayurvedics operates manufacturing facilities in Trichy, Tamil Nadu, India. The company specializes in the production of Ayurvedic pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding plant capacities and specialized manufacturing processes are not publicly disclosed. The facilities are designed to adhere to stringent quality standards, ensuring the efficacy and safety of their products.

The leadership team at Ashtanga Vaidyam Ayurvedics includes:

• Soolapani Thekke Variam Varier: Managing Director, appointed on 27 July 2016.

• Sasi Thirumuppath Raghavan: Whole-Time Director, appointed on 27 July 2016.

• Madhavan Unnikrishnan: Additional Director, appointed on 21 May 2025.

• Girish Sasi Varrier: Additional Director, appointed on 21 May 2025.

These individuals play pivotal roles in steering the company's strategic direction and operations.

Ashtanga Vaidyam Ayurvedics has a presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company exports finished pharmaceutical formulations, such as Taila, Arishta, Kwatha, Asava, and Ghrita, with a total export value of $146,000 USD across 583 shipments. These products are classified under the Ayurvedic & Herbal Products category. Specific details regarding regulatory filings, approvals, and market access status in these regions are not publicly disclosed.

Ashtanga Vaidyam Ayurvedics has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's commitment to quality and adherence to international standards have facilitated its entry into these regions. While specific details regarding WHO prequalification and other certifications enabling access to these markets are not publicly disclosed, the company's global footprint indicates a strategic approach to market diversification.

The company's export portfolio is entirely concentrated in the Ayurvedic & Herbal Products category, with the top five products accounting for 100% of the export value. This indicates a high level of portfolio concentration, which may expose the company to risks associated with market fluctuations and regulatory changes in the Ayurvedic sector. Diversifying the product portfolio and exploring new therapeutic categories could mitigate such risks and enhance the company's market resilience.

Specific details regarding Ashtanga Vaidyam Ayurvedics' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed. The company's export data indicates a presence in the U.S. market, suggesting compliance with FDA regulations for the export of Ayurvedic pharmaceutical formulations. However, without publicly available records, a comprehensive assessment of the company's FDA status cannot be conducted.

Ashtanga Vaidyam Ayurvedics' commitment to quality is evident in its adherence to international standards. While specific details regarding WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not publicly disclosed, the company's global export activities suggest compliance with these standards. However, without publicly available records, a comprehensive assessment of the company's certifications cannot be conducted.

Ashtanga Vaidyam Ayurvedics operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds manufacturing licenses and approvals from state drug controllers, ensuring compliance with Indian pharmaceutical regulations. Specific details regarding export No Objection Certificates (NOCs) and other regulatory approvals are not publicly disclosed. The company's export data indicates adherence to Indian regulatory standards for the export of Ayurvedic pharmaceutical formulations.

As of March 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Ashtanga Vaidyam Ayurvedics. The absence of such records suggests that the company maintains a compliant status with regulatory authorities. However, without publicly available records, a comprehensive assessment of the company's regulatory history cannot be conducted.

Ashtanga Vaidyam Ayurvedics operates in the Ayurvedic pharmaceutical sector, competing with other manufacturers of Ayurvedic formulations. While specific market share data and a head-to-head analysis are not publicly available, the company's export data indicates a presence in various international markets, suggesting a competitive position in the global Ayurvedic pharmaceutical industry. The company's focus on quality and adherence to international standards contribute to its competitive edge.

Ashtanga Vaidyam Ayurvedics' key differentiators include its longstanding heritage in Ayurvedic medicine, established in 1936, and its commitment to quality and innovation. The company's product portfolio, consisting of over 300 formulations, reflects its dedication to providing a diverse range of Ayurvedic solutions. Additionally, the company's focus on research and development for innovative natural therapies and its collaborations with leading firms in the field further distinguish it in the market.

Ashtanga Vaidyam Ayurvedics' current strategic direction focuses on the manufacturing and export of Ayurvedic pharmaceutical formulations. The company's emphasis on quality, research and development, and adherence to international standards positions it well in the global market. Future strategic initiatives may include diversifying the product portfolio, exploring new therapeutic categories, and expanding into additional international markets to enhance growth and mitigate risks associated with market concentration.

Ashtanga Vaidyam Ayurvedics has demonstrated a consistent track record in the export of Ayurvedic pharmaceutical formulations, with a total export value of $146,000 USD across 583 shipments. The company's reliability is indicated by its established presence in various international markets and its adherence to quality standards. However, specific details regarding export volume consistency and other reliability indicators are not publicly disclosed.

Importers should verify the following certifications when considering products from Ashtanga Vaidyam Ayurvedics:

• FDA Facility Registration: Confirm the company's registration status with the U.S. Food and Drug Administration.

• WHO-GMP Certification: Ensure compliance with World Health Organization Good Manufacturing Practice standards.

• EU GMP Certification: Verify adherence to European Union Good Manufacturing Practice standards.

• ISO Certification: Check for relevant International Organization for Standardization certifications.

To verify these certifications, importers can request copies of the certificates directly from the company or consult the respective regulatory bodies' official databases.

When conducting due diligence on Ashtanga Vaidyam Ayurvedics, importers should consider the following steps:

• Verify Regulatory Certifications: Confirm the validity of FDA, WHO-GMP, EU GMP, and ISO certifications.

• Assess Financial Health: Review the company's financial statements and credit history.

• Evaluate Product Quality: Request product samples and assess quality standards.

• Check Export Records: Review the company's export history and client references.

• Inspect Manufacturing Facilities: If possible, conduct site visits to evaluate manufacturing practices.

Red flags to watch for include expired or invalid certifications, inconsistent financial records, quality complaints, and negative client feedback. Recommended pre-order checks involve obtaining third-party audits and consulting industry peers.